Everything tagged "dividend" across research, earnings, and macro.
108 articles
Cencora is using specialty expansion and GLP-1 volume to grow earnings faster than revenue. The stock looks constructive for medium-term investors, with solid guidance and a reasonable forward valuation.
Kraft Heinz offers a defensive cash-generating profile, but weak revenue trends and impairment-driven earnings pressure keep the story in Hold territory. The upside depends on whether improving share in Taste Elevation can translate into durable organic growth.
Assurant is a high-quality compounder with embedded distribution in mobile, auto, and housing protection. Strong cash generation, improving earnings, and a flexible balance sheet support a Buy view.
Fresenius Medical Care posted a sharp 2025 profitability step-up, but 2026 is a transition year as temporary benefits roll off and rollout costs rise. The stock looks like a measured Buy for investors willing to wait for execution to stick.
FedEx is showing faster-than-expected improvement in its core parcel and express business as Network 2.0, pricing, and mix drive margin expansion. The upcoming FedEx Freight spin-off should further simplify the story, though valuation and leverage still limit the upside.
BBVA combines double-digit earnings growth, strong capital, and shareholder returns with a valuation that still looks reasonable. The report argues the bank merits a Buy as Spain and Mexico continue to drive results.
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
Atmus Filtration Technologies pairs a durable aftermarket core with a new industrial air-filtration growth leg. The stock earns a Buy on solid execution, margin expansion, and a fair value anchored at $66.
Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.
Clorox rebuilt profitability in fiscal 2025, but FY2026 guidance was cut sharply as ERP-related inventory drawdown hit sales and margins. The stock looks like a steady staples franchise in repair, with valuation close to fair and upside tied to execution.
WisdomTree has evolved into a broader asset-management platform with record AUM, rising margins, and multiple growth engines beyond its core ETF franchise. The stock looks like a credible Buy as flows, profitability, and free cash flow continue to improve.
Parker-Hannifin is a high-quality industrial compounder with accelerating aerospace exposure, record quarterly earnings, and strong free cash flow. The stock looks attractive on pullbacks, but valuation already prices in a lot of that strength.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator